department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

CLADRIBINE · pharmadog

pharmadog
drugs
CLADRIBINE

drug

patient view →

CLADRIBINE

Marketedupdated 2mo ago

by EMD Serono Inc

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 14 investigational indications.

all catalysts(1)

approval · 1

CLADRIBINE — FDA approval

News(0)

no news has mentioned this drug yet

brand

CLADRIBINE

generic

CLADRIBINE

indication

Relapsing Remitting Multiple Sclerosis (RRMS)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 2h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 23, 2038

~12.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (3)

Sep 10, 2041method-of-use (U-4395)US 12533408
Sep 10, 2041method-of-use (U-4399)US 12539329
Nov 23, 2038method-of-use (U-3411)US 10849919

🐶 often sniffed alongside

top 3

tagApproval4 co-mentions · 2 sources
tagSmall Molecule2 co-mentions · 2 sources
drugCRD-12 co-mentions · 2 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying CLADRIBINE

phase3Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)recruitingn=264
phase2Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasmsrecruitingn=62
phase2A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)recruitingn=86
phase2Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutationsrecruitingn=68
phase2Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLrecruitingn=20
phase2Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLrecruitingn=40
phase2BCL2i CLAG-M in R/R Acute Myeloid Leukemiarecruitingn=52
phase3Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvageterminatedn=167

more trials →